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ABSTRACT 
Assessment of Degradation for Porous PCL-PLLA Semi-IPN Shape Memory Polymer (SMP) 
Implants for Cranial Bone Defect Repair 
 
 
Abigail A. Roth 
Department of Biomedical Engineering 
Texas A&M University 
 
 
Research Advisor: Dr. Melissa A. Grunlan 
Dept. of Biomedical Engineering, Dept. of Materials Science, Dept. of Chemistry 
Texas A&M University 
 
Within cranial bone defect treatments, autografts remain the current gold standard for 
best healing outcomes. However, if the defect is of a unique shape, this process proves difficult 
and often requires additional surgeries. The work herein focuses on a regenerative approach 
utilizing a shape memory polymer (SMP) scaffold that can “self-fit” into a defect while 
maintaining important properties for healing (e.g. osteoconductivity, robustness, degradability).  
Poly(ε-caprolactone) (PCL) is an extensively studied SMP but, alone, is limited in bone 
repair due to its relatively low modulus and slow degradation rate for adequate bone healing.[1-3] 
To improve these properties, our group reported SMPs comprised of a semi-interpenetrating 
network (semi-IPN) of cross-linked PCL diacrylate (PCL-DA) and poly(L-lactic acid) (PLLA), 
which have shown great potential.[4, 5] Here, we investigated the degradation behavior of porous 
PCL-PLLA semi-IPN SMP implants in vitro under both accelerated conditions and non-
accelerated conditions towards ultimately predicting in vivo performance. Rapid degradation 
with greater PLLA wt% content was observed, along with mass losses up to ~9% at 5 months 
real-time degradation. Additionally, degradation was unaffected by the compressed implant 
“fitting” process, yet slightly accelerated by the application of a bioactive surface coating.  
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SECTION I 
INTRODUCTION 
 
Biodegradable, porous SMP scaffolds are a promising solution to heal bone defects as 
they would be able to (1) facilitate neotissue ingrowth and nutrient and waste transport, (2) 
maximize interfacial contact with the surrounding native bone and (3) degrade upon tissue 
regeneration. Due to the shape memory nature, such scaffolds based on cross-linked poly(ε-
caprolactone) diacrylate (PCL-DA) have been found to become malleable and amenable to 
“press-fitting” into model cranial bone defects when slightly heated (T > Ttrans; Ttrans = ~55 °C).[6] 
Upon subsequent cooling (T < Ttrans; i.e. body temperature), the scaffolds maintain their new, 
rigid shape within the defect. This is enabled by the melting and recrystallization of “switching 
segments” (i.e. semi-crystalline lamellae) as well as “netpoints” (i.e. chemical cross-links) which 
define the original shape.[7] The “fitting” behavior is critical to achieving high contact with 
adjacent bone tissue. Such contact is required for osseointegration with the surrounding tissue 
and is a feature lacking in many autografting procedures.[8] Moreover, unlike common injectable 
fillers that cure in situ, the porous SMP scaffolds’ properties (e.g. modulus, porosity, etc.) are 
conveniently established a priori.  
Our group has previously reported extensively on the potential of a porous, SMP scaffold 
based on PCL-DA for cranial bone defect repair.[5] High porosity was observed in addition to 
excellent shape memory behavior. Additionally, a developed polydopamine coating was applied 
to scaffold surfaces and found to increase hydrophilicity, impart bioactivity and enable 
osteoinductivity, all towards the potential to bond well to adjoining bone.[6] Despite favorable 
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scaffold properties, it was determined that an increase in scaffold rigidity, in addition to 
enhanced, controlled rates of scaffold degradation would ultimately improve healing outcomes. 
In addition to poly(ε-caprolactone) (PCL), and poly(L-lactic acid) (PLLA) has been 
extensively studied for biomedical applications.[9] PLLA exhibits a high modulus and has been 
often copolymerized or physically blended with PCL to improve the mechanical properties of 
PCL. Some approaches have also yielded faster degradation rates versus PCL alone.[1, 2, 10] Still, 
such blends’ and copolymers’ degradation rates are anticipated to be still too slow for success in 
bone regeneration.  
More recently, our group reported the properties of semi-interpenetrating networks (semi-
IPNs) comprised of cross-linked PCL-DA and thermoplastic PLLA.[4, 11] Initially, non-porous 
materials were prepared with varying weight % ratios of PCL:PLLA and the properties 
evaluated. The PCL-DA degree of polymerization (n; n = 25, 45) was also investigated. Findings 
included improved mechanical properties via an increase in ‘n’ (e.g. strength) and an increase in 
PLLA within the PCL:PLLA wt% ratio (e.g. modulus). Importantly, rates of degradation also 
increased with PLLA content within the PCL:PLLA wt% ratio. 
These previous works concluded in realizing the potential for the PCL-PLLA semi-IPN 
SMP scaffolds in the regeneration of cranial bone defects. The rates of degradation observed 
were thought to be particularly interesting. However, the degradation analysis has previously 
been limited to accelerated (i.e. high pH solution conditions) testing.[12] Moreover, the effect of 
pore compression upon implant “fitting” on scaffold degradation has not been considered, 
despite the potential for the compression to impede the rate of water diffusion. Herein, a study to 
fully assess scaffold implant degradation has been conducted towards predicting in vivo implant 
behavior. PCL-PLLA semi-IPN scaffold implants were prepared via a solvent-casting 
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particulate-leaching (SCPL) fabrication technique (Figure 1). Taking into account preparative 
implant considerations, the effects of compressed implant “fit” on degradation, in addition to the 
implications of the hydrophilic, polydopamine surface coating on degradation, were evaluated. 
Further, semi-IPN PCL:PLLA wt% ratios (100:0 [PCL-DA control], 90:10, 75:25, 60:40) and 
PCL-DA average degree of polymerization were varied (n = 25, 45). The PLLA average degree 
of polymerization (m) was maintained at m = 90. Degradation was evaluated under both 
accelerated conditions, to efficiently evaluate implant properties’ effects on degradation, and 
under non-accelerated, real-time conditions, to closely simulate in vivo degradation.  
 
 
 
Figure 1. Schematic of SMP scaffold implant fabrication procedure.  
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SECTION II 
MATERIALS AND METHODS 
 
Materials 
 Polycaprolactone diol (PCL90-diol; Mn ~ 10,000 g/mol), ε-caprolactone, L-lactide, 
stannous 2-ethylhexanoate, triethylamine (Et3N), acryloyl chloride, 4-dimethylaminopyridine 
(DMAP), 2,2-dimethoxy-2-phenylacetophenone (DMP), 1-vinyl-2-pyrrolidinone (NVP), 
potassium carbonate (K2CO3), sodium hydroxide (NaOH), phosphate-buffered saline (PBS; 1X, 
pH = 7.4), ethylene glycol, and solvents were obtained from Sigma-Aldrich. Anhydrous 
magnesium sulfate (MgSO4) was obtained from Fisher. Reagent CH2Cl2 and NMR-grade CDCl3 
were dried over 4 Å molecular sieves before use. 
Polymer Synthesis 
 PCL2n-diol (n = 25, 45) and PLLA2m-diol (m = 90) were synthesized by the ring-opening 
polymerization of ε-caprolactone or l-lactide, respectively, with an ethylene glycol initiator and 
stannous 2-ethylhexanoate catalyst. The ethylene glycol initiator to monomer ratio controlled the 
degree of polymerization in both polymers (n, m). The resulting terminal hydroxyl groups of 
PCL2n-diol were then replaced by photosensitive acrylate (OAc) groups by reacting with 
triethylamine and acryloyl chloride. The number average molecular weights (Mn) and degree of 
acrylation were determined by 1H NMR.  
Fabrication 
 In order to fabricate each specimen, SMP scaffolds were prepared using a previously 
reported solvent-casting particulate-leaching (SCPL) method.[13, 14] First, NaCl particles were 
sieved with openings of 425 µm resulting in particles with a diameter of 527 ± 92 µm. This was 
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verified using ImageJ software and SEM images. 10 g of the collected NaCl particles were 
placed in a 20 mL glass vial and fused with 7.5 wt% DI water added in four increments and 
mechanically stirred after each addition. The mixture was centrifuged (3,220G, 15 minutes), air-
dried for an hour, and dried in vacuo overnight at room temperature. 
 Macromer solutions (0.15 g mL-1 CH2Cl2, ~4 mL solution/ SMP scaffold) were prepared 
with varying PCL:PLLA wt% ratios (100:0, 90:10, 75:25, 60:40), along with 15 vol% 
photoinitiator solution (10 wt% DMP in NVP). The solutions were added to the salt template and 
centrifuged (1,260G, 10 minutes) prior to being exposed to UV light for 5 minutes and air-dried 
overnight. The SMP scaffolds were removed from the vials and submerged in water/ethanol (1:1 
vol:vol) solution for 7 days with regular solution changes in order to leach out the NaCl particles 
(Figure 1).  
After removal from solution and air-drying, the SMP scaffolds were annealed in vacuo at 
160 °C for 10 minutes in order to induce the densification requisite for shape memory 
capabilities while also maintaining equivalent porosity between the PCL:PLLA ratios.[5] Each 
scaffold was then sectioned into three specimens (~1.75 mm thick) using a vibratome and 
punched to a 9 mm diameter. Finally, the implants were briefly treated at 85 °C to recover any 
deformation occurring during processing.  
 To investigate the effects on degradation of a compressed implant upon defect “fitting,” 
select implants (75:25; PCL-DA, n = 45) underwent simulated “fitting” within a model defect. 
The fabricated, 9 mm implants were submerged in warm water (~60 °C, T > Ttrans) and, via shape 
memory behavior, were subsequently “fitted” into an 8 mm model defect. Upon cooling (T < 
Ttrans), the now-compressed implant was removed from the defect mold and dried in vacuo prior 
to evaluation of pore morphology and degradation rate under accelerated conditions. 
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Additionally, to study the effect of the a previously-studied, bioactive polydopamine 
coating on implant degradation, select implants (75:25; PCL-DA, n = 45) were surface-coated as 
previously reported.[6] Briefly, the fabricated implants were degassed using a syringe and 
suspended in a dopamine hydrochloride solution (2 mg mL-1 in 10 mM Tris buffer, pH = 8.5) at 
150 rpm for 16 h. After, they were extensively rinsed with DI water and dried in vacuo prior to 
evaluation of degradation rate under accelerated conditions. 
Characterization 
Scanning Electron Microscopy 
 SEM imaging were used to compare the morphology of pores along the implant 
perimeter before and after simulated “fitting” for implants of the varying PCL:PLLA ratios. The 
implants were coated with Au-Pt, and then images were taken using a JEOL 6400 SEM with an 
accelerating voltage of 10 kV.  
Accelerated Degradation 
 Implants (N = 3, per time point) were immersed in 10 mL of 0.1 M NaOH and 
maintained at 37°C at 60 rpm. At specified time-points, implants were removed and blotted dry 
followed by drying in vacuo overnight. The mass loss of each implant was determined and 
compared to the initial mass using Equation (1). 
   𝑀𝑎𝑠𝑠	𝐿𝑜𝑠𝑠	(%) = 	+,-,.,/0	1	+2,-/0+,-,.,/0 	× 	100    (1). 
 Mass loss of SMP implants of the varying PCL:PLLA wt% ratios (100:0, 90:10, 75:25, 
60:40) and PCL molecular weight (n = 25, 45) was evaluated at 24, 72, 120, and 168 h. Mass 
loss of “fitted” implants (75:25; PCL-DA [n = 45]) and the corresponding “non-fitted” controls 
was evaluated at 120 h, and the mass loss of polydopamine-coated implants (75:25; PCL-DA [n 
= 45]) and the un-coated controls was evaluated at 24, 72, 120 and 168 h.  
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Neutral Degradation 
 Specimens (N = 3, per time point) comprised of the varying PCL:PLLA wt% ratios 
(100:0, 90:10, 75:25, 60:40) and PCL molecular weight (n = 25, 45) were immersed in 10 mL of 
phosphate-buffered saline (PBS, pH = 7.4) in a sealed 20 mL vial maintained at 37 °C at 60 rpm. 
At 1, 3, and 5 months, the respective samples were removed from the solution, blotted dry, and 
dried in vacuo overnight at room temperature. The mass of each specimen was determined and 
compared to the initial mass using Equation (1). 
Water Uptake 
 Specimens (N = 3, per time point) comprised of the varying PCL:PLLA wt% ratios 
(100:0, 90:10, 75:25, 60:40) and PCL molecular weight (n = 25, 45) were each immersed in 10 
mL of phosphate-buffered saline (PBS) in a sealed 20 mL vial maintained at 37 °C at 60 rpm. At 
1, 3, and 5 months, the respective samples were removed from the solution and blotted dry. The 
mass of the implants before and after drying in vacuo was measured and used to calculate water 
update using Equation (2). 
   𝑊𝑎𝑡𝑒𝑟	𝑈𝑝𝑡𝑎𝑘𝑒	(%) = 	+=>.	1	+?@A+?@A 	× 	100    (2). 
Statistical Analysis 
 Data was reported as the mean ± standard deviation. Values were compared using either 
two-way Anova or a Student’s t-test to determine p-values. 
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SECTION III 
RESULTS AND DISCUSSIONS 
 
Fabrication 
 Porous scaffolds were successfully fabricated using the SCPL method and 160 °C-
annealing (Figure 1). Sectioning to a ~2 mm thickness and punching to a diameter of 9 mm 
resulted in a 9 x 2 mm scaffold implant. Previous work confirmed the PCL:PLLA wt% ratios via 
TGA and maintained scaffold properties (e.g. pore morphology) upon processing.[5] 
Accelerated Degradation 
In previous work,[5] degradation trends via mass loss under accelerated conditions (1 M 
NaOH, 37 °C) were studied using PCL-PLLA semi-IPN scaffold cylinders (5 x 12 mm). 
Although the general trends of more rapid degradation with increasing PLLA content within the 
semi-IPN PCL:PLLA wt% ratio, degradation occurred quickly for the 75:25 and 60:40 
(PCL:PLLA wt%; PCL-DA [n = 45]) compositions, degrading completely by 72 h. In this work, 
scaffolds processed to implantation-ready discs (9 x 2 mm) were studied to better evaluate 
degradation. Additionally, the degradation solution concentration utilized for the accelerated 
hydrolysis testing (0.1 M NaOH, 37 °C, 60 rpm) was reduced in order to observe a fuller 
degradation profile. Additionally, the accelerated conditions (0.1 M NaOH, 37 °C, 60 rpm) were 
used to determine the effects of compressed implant “fit,” as well as an applied polydopamine 
surface coating, on degradation. Both preparatory factors have the potential to affect degradation 
in vivo and, thus, were considered in vitro. 
Since the rate of degradation depends on amount of surface area in contact with the 
medium, the compressed state of the implant after “fitting” within a defect could limit diffusion 
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into the implant. Thus, the morphology and degradation behavior of a compressed, “fitted” 75:25 
(PCL:PLLA wt%; PCL-DA [n = 45]) implant was compared to non-compressed implants. While 
the pore morphology along the compressed, “fitted” implant edge revealed signs of pore 
compression for all implant compositions (Figure 2a), hydrolytic degradation (75: 25 
PCL:PLLA wt%; PCL-DA [n = 45]) via accelerated mass loss was not significantly affected at 
120 h (Figure 2b). This could be attributed to the non-compressed state of the pores on the faces 
of the implant, which also possess a greater surface area than the “fitted” edges. As a result, in 
vitro degradation studies of initial, non-compressed implants are expected to be highly 
representative of analogs ultimately “fitted” within a cranial bone defect.  
 
 
Figure 2. a) Photo series depicting a simulated implant “fitting” process within a model defect and SEM images of 
the circumferential implant edge before and after the “fitting.” Morphologically, the perimeter edge of the implants 
becomes slightly compressed after being “fitting” via shape memory. b) Mass loss under accelerated conditions (0.1 
M NaOH, 37 °C, 60 rpm) for 75:25 (PCL:PLLA wt%) scaffold implants (PCL-DA [n = 45]) at 120 h (# p > 0.05 vs 
corresponding non-compressed control). 
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In order to facilitate osteoinduction, a bioactive polydopamine coating can be applied to 
the surface of the implants. Previous work showed increased mineralization upon exposure to 
simulated body fluid and an osteogenic cellular response,[6] indicating potentially improved 
healing in vivo. In this study, implants (75:25 PCL:PLLA wt%; PCL-DA [n = 45]) were coated 
with polydopamine and subjected to accelerated degradation conditions (0.1 M NaOH, 37 °C, 60 
rpm). The degradation rates via mass loss were then compared to an analogous, uncoated 
scaffold implant (Figure 3). The resulting degradation rate proved to be slightly increased for 
coated implants. This finding was expected due to dopamine’s polar amine and hydroxyl 
functional groups. The coating also increases hydrophilicity of the surface and, consequently, 
hydrolysis. The observed tunability of degradation rate via scaffold coating could be favorable. 
   
 
 
Figure 3. Mass loss under accelerated conditions (0.1 M NaOH, 37 °C, 60 rpm) for 75:25 (PCL:PLLA wt%) 
scaffold implants (PCL-DA [n = 45]) either without or with an applied polydopamine coating. Significance was 
observed at 120 h (*p < 0.05 vs corresponding uncoated control). 
  
 
In addition to examining the effects of preparative implant considerations, the effect of 
the PCL:PLLA wt% ratio and PCL-DA ‘n’ on implant degradation were also evaluated under 
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accelerated conditions (0.1 M NaOH, 37 °C, 60 rpm) (Figure 4a, Figure 4b). As hypothesized, 
implants with greater PLLA content degraded more quickly. After 168 h, the PCL-DA control (n 
= 25, 45) displayed a mass loss of only ~0.5% and ~2% respectively, while the 60:40 
(PCL:PLLA wt%; PCL-DA [n = 25, 45]) compositions lost ~63% and ~79% mass. The observed 
differences between implants prepared with either PCL-DA (n = 25) or PCL-DA (n = 45) has 
been attributed to the increased number of hydrolytically-labile ester bonds in PCL-DA (n = 25) 
scaffolds.[15] Additionally, the implantable discs displayed visual fragmentation and decreased 
mechanical integrity at later stages of degradation (Figure 4c). The observation could indicate a 
bulk erosion mechanism.[16]  
 
 
Figure 4. Mass loss under accelerated conditions (0.1 M NaOH, 37 °C, 60 rpm) for PCL-PLLA scaffold implants 
prepared with either a) PCL-DA (n = 25) or b) PCL-DA (n = 45). c) Images of scaffold implants at different time 
points throughout degradation. 
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Non-accelerated Degradation 
In addition to accelerated testing, the PCL-DA control and PCL-PLLA semi-IPN scaffold 
implants were subjected to non-accelerated, real-time conditions (PBS [pH = 7.4], 37 °C, 60 
rpm) to further investigate the degradation. Mass loss of the implants was assessed at 1, 3, and 5 
months (Figure 5a, Figure 5b). Water uptake as also considered. By 5 months of non-
accelerated degradation, mass loss was observed to increase, generally corresponding with PLLA 
content with the PCL-PLLA semi-IPN scaffolds. In this study, there was no observable 
difference in implant appearance post-degradation (Figure 5c). Thus, the mechanism of erosion 
is unclear pending a greater extent of degradation in future studies.  
 
 
Figure 5. Mass loss under non-accelerated conditions (PBS [pH = 7.4], 37 °C, 60 rpm) for PCL-PLLA scaffold 
implants prepared with either a) PCL-DA ( n = 25) or b) PCL-DA (n = 45). c) Images of scaffold implants at 
different time points throughout degradation. 
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At 5 months degradation, water uptake was quantified, and an increase in water uptake 
was observed in certain PCL-PLLA semi-IPN scaffold implants over the corresponding PCL-DA 
control implants (Figure 6a). The greater uptake implies an increase in water diffusion and 
absorption and could indirectly indicate greater hydrophilicity as well. The findings have been 
previously attributed to phase separation and a decrease in crystallinity.[5] Correspondingly, at 5 
months, the PCL-DA controls prepared with PCL-DA (n = 25) and PCL-DA (n = 45) exhibited 
an average mass loss of ~1.4% and ~2.3%, respectively (Figure 6b). On the other hand, the 
60:40 (PCL:PLLA wt%; PCL-DA [n = 25, 45]) scaffolds lost an average of ~6.4% and ~8.6% 
mass, respectively.  
 
 
Figure 6. a) Water uptake under non-accelerated conditions (PBS [pH = 7.4], 37 °C, 60 rpm) for PCL-PLLA 
scaffold implants at 5 months (*p < 0.05, **p < 0.01 vs corresponding PCL-DA control implant). b) Corresponding 
mass loss under non-accelerated conditions (PBS [pH = 7.4], 37 °C, 60 rpm) for PCL-PLLA scaffold implants at 5 
months (**p < 0.01 vs corresponding PCL-DA control implant; +p < 0.05 vs corresponding PCL-DA (n = 25) 
composition). 
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The amount of PLLA within the semi-IPN PCL:PLLA wt% ratio contributed to greater 
rates of mass loss and degradation under both accelerated and non-accelerated conditions. Under 
non-accelerated conditions, however, an increase in degradation was observed for 75:25 
(PCL:PLLA wt% ratio) implants when prepared with PCL-DA (n = 45) over PCL-DA (n = 25) 
implants. While different from observations under accelerated conditions, the finding may be due 
to a reduced crosslink density within the PCL-DA (n = 45) scaffolds, despite no noticeable 
difference in measured water uptake. Further studies will discern if the observed differences can 
be attributed to differences in semi-IPN scaffold properties or if there is a limitation of water 
uptake analysis. 
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CONCLUSION 
 
 Porous, SMP scaffold implants comprised of semi-IPNs of cross-linked PCL-DA and 
thermoplastic PLLA have the potential to be “fitted” within irregular defects, promoting healing 
while also possessing favorable and tunable properties. In this work, scaffold implant 
degradation and tunability were further assessed. Accelerated degradation testing (0.1 M NaOH, 
37 °C, 60 rpm) investigated the effect of preparative implant considerations on degradation. The 
designed process of “fitting” scaffold implants within cranial bone defects via shape memory 
behavior was found to have no significant effect on degradation rate. Additionally, a developed, 
bioactive polydopamine coating applied to the surfaces of the scaffold implants contributed to 
greater rates of degradation. Lastly, the porous implants exhibited greater extends of mass loss 
with increasing PLLA content within the semi-IPN PCL:PLLA wt% ratio.  
Furthermore, non-accelerated testing (PBS [pH = 7.4], 37 °C, 60 rpm) served to best 
simulate and predict in vivo degradation behavior. Degradation initially closely paralleled the 
trends observed under accelerated degradation conditions, and water uptake was determined to 
be greater in semi-IPNs with greater PLLA content within the PCL:PLLA wt% ratio. Future 
work will study such degradation up to twelve months, providing additional conclusions.  
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